Original Research

Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice

Liu K, Wu J, Xu Y, Li D, Huang S, Mao Y

OncoTargets and Therapy 2022, 15:1079-1094

Published Date: 1 October 2022